← Back to Influence Map
Entity DossierOrganization
ASSOCIATION FOR ACCESSIBLE MEDICINES
DC · US
National trade organization representing the interests of generic drug manufacturers.
Tracked direct giving
$0
LDA reported lobbying spend
$6,200,000
Connections
10
Lobbying Activity Detail
Disclosed lobbying expenditures from LDA filings where this entity is the client. Dollar amounts represent what was reported to the Senate Office of Public Records.
Top Lobbying Issues
TRDTrade
$10.3MPHAPharmacy
$10.1MCPTCopyright/Patent/Trademark
$9.9MMMMMedicare/Medicaid
$9.3MBUDBudget/Appropriations
$5.7MHCRHealth Issues
$900KLBRLabor/Employment
$510KMANManufacturing
$400KLobbying Firms Retained
In-house lobbyists (filed as its own registrant)$9.3M
THE GIBSON GROUP, LLC$510K
Foley & Lardner LLP$400K
RUBIN, TURNBULL & ASSOCIATES$350K
SQUIRE PATTON BOGGS$170K
FEROX STRATEGIES$90K
TWINLOGIC STRATEGIES, LLP$70K
Foley & Lardner$0
Bills Referenced in Lobbying Filings
march-ininsulin
Lobbying data from Senate LDA filings and the LobbyView dataset (MIT/NSF, CC-BY-4.0). Dollar figures represent disclosed expenditures only and may not capture all influence activity. Issue codes follow the LDA general issue classification.
Connection Graph
0 nodes · 0 edgesHover for labels · Double-click to expand
Loading graph...
Person
Organization
PAC
Gov Body
Legislature
Think Tank
Industry
Outcome
Click a node to see details
Double-click to expand its connections
Relationships
| Type | Connected To | Details | Source |
|---|---|---|---|
| Retained | Foley & Lardner | Hired FOLEY & LARDNER LLP to lobby on Pharmaceuticals | Source |
| Retained | THE GIBSON GROUP, LLC | Hired THE GIBSON GROUP, LLC to lobby on Pharmaceuticals | Source |
| Commented on | Centers for Medicare & Medicaid Services | Public comment on CMS-2023-0187: Medicare Program: Contract Year 2025 Policy and Technical Changes to the Medicare Advantage Program, Medicare Prescription Drug Benefit Program, Medic | Source |
| Lobbied on | MARCH-IN Rights Proposal (NIH Framework) | LDA filing: lobbied on NIH March-In Rights, period 1st Quarter (Jan 1 - Mar 31), reported amount $510,000 | Source |
| Lobbied on | Insulin Price Caps - State-Level Legislation | LDA filing: lobbied on Insulin Price Caps, period 1st Quarter (Jan 1 - Mar 31), reported amount $480,000 | Source |
| Retained | Foley & Lardner LLP | Hired FOLEY & LARDNER LLP to lobby on Pharmaceuticals | Source |
| Retained | SQUIRE PATTON BOGGS | Hired SQUIRE PATTON BOGGS to lobby (1st Quarter (Jan 1 - Mar 31) 2025) | Source |
| Retained | RUBIN, TURNBULL & ASSOCIATES | Hired RUBIN, TURNBULL & ASSOCIATES to lobby (4th Quarter (Oct 1 - Dec 31) 2025) | Source |
| Retained | TWINLOGIC STRATEGIES, LLP | Hired TWINLOGIC STRATEGIES, LLP to lobby (1st Quarter (Jan 1 - Mar 31) 2026) | Source |
| Retained | FEROX STRATEGIES | Hired FEROX STRATEGIES to lobby (1st Quarter (Jan 1 - Mar 31) 2026) | Source |